Clinical Trial Update: Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study evaluating immune reconstitution monitoring and pneumococcal vaccination in patients treated with CAR-T cells has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Leukemia
• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• CAR-T cell therapy

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Malignancy, Cancer | Phase 1, Phase 2 | Status: WITHDRAWN